New imaging agent could help doctors see hidden cancers
NCT ID NCT03164486
First seen Feb 28, 2026 · Last updated May 06, 2026 · Updated 8 times
Summary
This early-stage study tests a new radioactive tracer called 18F-αvβ6-binding-peptide to see if it can safely and effectively locate primary or metastatic cancers in the breast, colon, lungs, and pancreas. About 27 adults with these cancers will receive the tracer and undergo PET scans. The goal is to check for side effects and measure how well the tracer highlights tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of California Davis Comprehensive Cancer Center
Sacramento, California, 95817, United States
Conditions
Explore the condition pages connected to this study.